Management of Advanced Non-Small Cell Lung Cancer (NSCLC) and Clinical Outcomes in Patients Who Received Gefitinib in Thailand
Completed
- Conditions
- Lung Cancer
- Registration Number
- NCT01130961
- Lead Sponsor
- AstraZeneca
- Brief Summary
The purpose of this study is to determine progression-free survival of lung cancer patients who received gefitinib in clinical practice in Thailand.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 104
Inclusion Criteria
- Diagnosed as having lung cancer based on histological/cytological findings
- Admitted to the hospital between January 2004 and December 2008
- Treated with gefitinib for at least 3 months
Exclusion Criteria
- Involvement in the planning and/or conduct of the study
- Participation in another clinical study during the last 3 months
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Progression-free survival median time from the first date of treatment until date of disease progression during Jan 2004- Dec 2008 or 5 years approx.
- Secondary Outcome Measures
Name Time Method Time to maximum response Median time from the first date of treatment until the date that the disease can be maximum controlled during Jan 2004- Dec 2008 or 5 years approx. Overall survival time from the first date of treatment until date of patients dead during Jan 2004- Dec 2008 or 5 years approx. Prevalence of EGFR & KRAS mutation from laboratory result During Jan 2004- Dec 2008 or 5 years approx.
Trial Locations
- Locations (1)
Research Site
🇹🇭Bangkok, Thailand
Research Site🇹🇭Bangkok, Thailand